{"title": "COVID-19 Clinical Trials", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2002-05-08", "cleaned_text": "Search Health Canada authorized clinical drug and vaccine trials for | | Intervention Authorization holder (Authorization date) | | Trial name (Health Canada Control #) Title Trial registry identifier | | Phase Recruitment status Start date Estimated study completion date | | Arms and Treatments | | Population Estimated enrollment | | Results | | Allogeneic Bone Marrow Mesenchymal Stromal Cells (BM-MSCs) and Allogeneic Umbilical Mesenchymal Stromal (UC-MSC) Ottawa Hospital Research Institute (2020-05-15) | | CIRCA-19 (Control # 238608) Cellular Immunotherapy for COVID-19 acute respiratory distress syndrome (ARDS) (CIRCA) the Vanguard Study NCT04400032 | | Phase 1 Completed Start Date: 2020, May 15 Study completion date: 2021, April 22 | | (Dose escalating and safety trial) Experimental 1: Mesenchymal Stromal Cells (MSCs) 25 million cells/unit dose (cumulative dose: 75 million MSCs) IV Experimental 2: MSCs 50 million cells/unit dose (cumulative dose: 150 million MSCs) IV Experimental 3: MSCs up to 90 million cells/unit dose (cumulative dose: up to 270 million MSCs) IV | | Adult, COVID-19, on invasive mechanical ventilation <48h, ARDS 9 participants | | Progressed to a Phase 2 RCT | | Allogeneic umbilical cord mesenchymal stromal cells (UC-MSCs) Ottawa Hospital Research (2021-04-13) | #250736) ARDS (CIRCA-19) randomized clinical trial NCT04865107 | | Phase 2 Recruiting Start Date: 2021, April 27 Estimated study completion date: 2022, April | | Experimental: UC-MSCs 3 doses daily up to 90 million cells/dose IV (max cumulative dose of 270 million calls) Placebo comparator: PlasmaLyte A and 5% Human Albumin 3 doses daily up to 90 million cells/dose IV (max cumulative dose of 270 million calls) | | 18+, SARS-CoV-2 positive, ARDS needing ventilation 54 participants | | No results posted | | Apabetalone (RVX000222) Resverlogix Corp (2021-04-06) | | RVX222-CS-023 (Control #250480) An open-label study to assess the safety and effect on clinical course and key biomarkers of oral apabetalone in hospitalized subjects with COVID-19 infection in addition to standard of care (SOC) NCT04894266 | | Phase 2 Not yet recruiting Start date: 2022, January 14 Estimated completion date: 2022, September 22 | | Experimental: Apabetalone 100mg BID + standard of care Comparator: standard of care | | 18+, SARS-CoV-2 positive, hospitalized 100 participants | | Not yet posted | | Apheresis frozen plasma from recovered COVID-19 patients (Convalescent Plasma) C17 Council (2020-05-04) | CONCOR-KIDS: A randomized, multicentered, open-label Phase 2 clinical trial of the safety and efficacy of human Coronavirus-immune convalescent plasma for the treatment of COVID-19 disease in hospitalized children NCT04377568 | | Phase 2 Withdrawn (no enrollment) Start date:2020, October 7 Withdrawal date: 2021, April 23 | | Experimental: Convalescent plasma 10mL/kg up to 500mL IV infusion (one dose) No Intervention: Clinical standard of care | | Children (<19 years), COVID-19, hospitalized 0 participants | | Withdrawn (no enrollment) | | Apheresis frozen plasma from recovered COVID-19 patients (Convalescent Plasma) Hamilton Health Sciences (2020-04-16) | | GRAAL-2020-01 (Control #238201) A randomized, open-label trial, of convalescent plasma for hospitalized adults with acute COVID-19 respiratory illness (CONCOR-1) NCT04348656 | | Phase 3 Terminated Start date: 2020, May 14 Study termination date: 2021, June 16 | | Experimental: ABO compatible convalescent apheresis plasma 500mL (1 unit of 500mL or 2 units of 250mL) No Intervention: Clinical standard of care | | 16 years +, COVID-19, hospitalized, receiving supplemental oxygen 940 participants | | Terminated (Study was terminated after the planned interim analysis as the pre-defined futility threshold was met) | | AT-527 (RO7496998) Hoffman La Roche Limited (2021-05-20) | | WV43042 (Control #252494) A phase II randomized double-blind, placebo controlled study to evaluate the antiviral activity safety, pharmacokinetics, and efficacy of RO7496998 (AT-527) in non-hospitalized adult patients with mild or moderate COVID-19 NCT04709835 | | Phase 2 Completed Start date: 2021, February 3 Study completion date: 2021, October 13 | | Experimental: AT-527 550mg BID Placebo comparator: placebo | | 18+, SARS-CoV-2 positive, outpatient 104 participants | | Did not meet the primary endpoint in the overall population of patients with mild or moderate COVID-19, who were mostly low-risk with mild symptoms In high-risk patients with underlying health conditions, a reduction of viral load was observed compared to placebo | | Baricitinib, Remdesivir, Tocilizumab Dr. Lisa Barrett (2020-04-14) | | SAIL-004 (control # 237708) Assessment of Investigational Medications adjunct to Clinical Standard of Care for Treatment of Moderate to Severe Coronavirus Disease (COVID-19) (in Hospitalized Patients) NCT04321993 | | Phase 2 Recruiting Start Date: 2020, April 17 Estimated study completion date: 2023 March | | Experimental: (moderate and severe, not critical disease) Baricitinib (janus kinase inhibitor) 4mg po daily for 14 days or until hospital discharge Experimental: (moderate and severe, not critical disease) Remdesivir (antiviral) 200mg IV over one hour (loading dose) on Day 1 followed by 100mg IV daily over one hour on Days 2-5 with possibility of extending up to 10 days) Experimental: (moderate and severe, not critical disease) Remdesivir (antiviral) 200mg IV over one hour (loading dose) on Day 1 followed by 100mg IV daily over one hour on Days 2-5 with possibility of extending up to 10 days) + Baricitinib (janus kinase inhibitor) 4mg po daily for 14 days or until hospital discharge Experimental: (severe, critical disease) Tocilizumab (interleukin 6 inhibitor) 8mg/kg total bodyweight up to 800mg max, IV over one hour No Intervention: Clinical standard of care | | Adult (18+), hospitalized, moderate to severe COVID-19 800 participants | | No results posted as of yet | | Bemnifosbuvir (BEM; AT-527) Atea Pharmaceuticals Inc. (2022-12-06) | | AT-03A-017 / control # 269964 (Authorized under the COVID-19 Regulations) A Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of bemnifosbuvir in high risk outpatients with COVID-19 NCT05614349 | | Phase 3 Recruiting Start Date: 2022, November 25 Estimated study completion date: 2024, January | | Experimental: Bemnifosbuvir (BEM) PO BID for 5 days EPlacebo Comparator: Placebo tablets PO BID q 5 days | | 18 + years, SARS-CoV-2 positive, high risk of disease progression 1500 participants | | No results posted as of yet | | Bovine lipid extract surfactant suspension (BLES) St Joseph's Health Centre London (2020-05-05) | | LESSCOVID (Control #238851) surfactant administration study for COVID19 (LESSCOVID) NCT04375735 | | Phase 1/2 Completed Start date: 2020, July 1 (estimated) Study completion date: 2021, October 6 | | Experimental: Bovine Lipid Extract Surfactant 2ml/kg via suction catheter through the ET tube daily for up to 3 doses, for as long as patient is on the ventilator No Intervention: Clinical standard of care | | Adult, COVID-19, Acute respiratory failure requiring intubation 20 participants | | Sponsor reported that: Due to the small sample size, no significant clinical benefit could be attributed to surfactant treatment. Safety established as no significant adverse events attributed to the surfactant treatment. No peer reviewed data/published results. | | BRII-196/BRII-198/AZD7442 National Institute of Allergy and Infectious Diseases (NIAID) (2021-04-08) | | ACTIV-2/A5401 (Control #250685) Authorized under the clinical trials interim order Adaptive platform treatment trial for outpatients with COVID-19 (Adapt Out COVID) NCT04518410 | | Phase 2/3 Active, not recruiting Study start date: 2020, August 19 Estimated study completion date: 2023, June 22r | | Experimental: BRII-196/BRII-198 1000mg/1000mg combo one dose IV infusion Experimental: AZD7442 one dose IV infusion Placebo comparator: 0.9% chloride solution one dose IV infusion Experimental: SNG001 1.3mL solution inhaled once daily for 14 14 days Experimental: AZD8895 300mg IM and AZD1061 300mg IM each sequentially Placebo comparator: chloride solution IM two injections sequentially Experimental: Camostat 200mg PO every 6 hours for 7 days Placebo comparator: Placebo tablets PO every 6 hours for 7 days Experimental: C135-LS 400mg SC and C144-SL injections Placebo comparator: Placebo SC 4 injections one dose | | 18+, SARS-CoV-2 positive, outpatient 8797 participants | | No Ramipril/ Perindopril/ (2020-10-16) | | CTO-3212 (Control #244591) filed under the IO Evaluation of the potential benefit of reninangiotensin system inhibitors (RASI, ACEI/ARB) in high risk patients with COVID-19 | | Phase 3 Recruiting Start date: 2021, January 27 Estimated study completion date: 2024, December | | No intervention: Clinical standard of care Experimental: ACE inhibitor (dose based on local practice) Experimental: ARB (dose based on local practice) | | 65+, COVID-19, high risk comorbidity 1155 participants | | No results posted | | Camostat Mesilate McGill University Health Centre (2020-07-02) | #240313) The impact of Camostat Mesilate on COVID-19 Infection: A randomized controlled Phase II Clinical Trial | | Phase 2 | | Camostat mesilate/Candesartan Vancouver General Hospital (2021-03-22) | | CAM-001 (Control #247212) Efficacy of camostat mesylate in reducing severity COVID-19 | | Therapeutics Inc. (2021-07-16) | | CARDIOL 100-03 (Control #254314) Study to evaluate the efficacy and safety of CARDIOLRX in patients with COVID-19 and cardiovascular disease or risk factors, a double-blind, placebo-controlled trial (LANCER) NCT04615949 | | Phase 2/3 Terminated Start date: April 30, 2021 Termination date: 2022, November 30 weight p.o. body weight p.o. b.i.d | | Adult (18+), SARS-CoV-2 positive, not in ICU 90 participants | | Terminated (The changing nature of COVID-19 including a more vaccinated population, increasing natural population immunity, milder variants and other related factors has meant that it is no longer realistic to recruit the patients in a reasonable time frame.) | | Carbon Dioxide and Perflubron (S-1226) SolAeroMed Inc. (2020-12-31) | | SAMI-05-1-01 (Control #247617) A randomized, open-label, controlled Phase II study to evaluate the safety, tolerability and efficacy of S-1226 in hospitalized subjects with moderate severity COVID-19 NCT04738136 | | Phase 2 Suspended (sponsors decision) Start date: February 15, 2021 (estimated) Estimated study completion date: December 31, 2021 | | Experimental: Standard of care + S-1226 inhaled at either 4%, 8%, or 12% CO2 twice daily for up to 5 days No intervention: Clinical standard of care | | Moderate COVID-19, hospitalized, experiencing bronchiolitis/pneumonia 30 participants | | Not yet posted | | Carbon Dioxide and Perflubron (S-1226) SolAeroMed Inc. (2021-06-21) | | SAMI-06-1-01 (Control #253521) A randomized, placebo-controlled phase II study to evaluate the safety, tolerability, and efficacy of S-1226 in post-COVID-19 subjects with persistent respiratory symptoms NCT04949386 | | Phase 2 Not yet recruiting Start date: September 2021 (estimated) Estimated study completion date: January | Experimental: Perfluorooctylbromide (PFOB) gas/aerosol/vapor in a 8% carbon dioxide medical gas mixture, inhaled for 3-4minutes, twice daily for 7 days Placebo comparator: Saline 3mL and medical grade air inhaled for 3-4 minutes | | Adults (18-80 years), evidence of new or persistent respiratory symptoms at least 4 weeks after the onset of acute COVID-19 infection 48 participants | | Not yet posted | | Chimeric interferon alpha (Novaferon) Genova Inc. (2020-12-11) | | JH-COR-003 (Control #246575) Authorized under the clinical trials interim order with terms and conditions NOVATION-1: A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of aerosolized novaferon + SOC vs. placebo + SOC in hospitalized adult patients with moderate to severe COVID-19 NCT04669015 | | Phase 3 Recruiting Start date: 2021, June 10 Estimated primary completion date: 2022, August | | Experimental: Novaferon 20ug BID (inhaled) for 10 days + clinical standard of care Placebo comparator: Formulated vehicle BID (inhaled) for 10 days + clinical standard of care | | 18+, SARS-CoV-2 positive, COVID-19 symptomatic, hospitalized 914 participants | | Not yet posted | | Cholecalciferol (Vitamin D3) Centre Hospitalier Universitaire Sainte-Justine (2020-09-16) | | PROTECT (Control #243196) Prevention of COVID-19 with Oral Vitamin D Supplemental Therapy in Essential Healthcare Teams NCT04483635 | | Phase 3 Terminated Start Date: 2021, February 8 Termination date: 2021, May 28 | | Experimental: Vitamin D3 10 tablets containing 10 000 IU PO once, followed by 10 000 IU once every week for 16 weeks Placebo Comparator: Placebo tablet 10 PO once, followed by 1 placebo tablet once a week for 16 weeks | | Adult age 18-70, Health Care workers working in settings with high-risk of contact with COVID-19 cases 34 participants | | Terminated (A premature discontinuation was recommended by the Data Safety Monitoring Board and agreed upon by the principal investigator, because the significantly lower recruitment than planned, in the context of mass vaccination of the target population.) | | Ciclesonide Research Institute of McGill University Health Centre (2020-05-23) | | Mild-CONTAIN 2021-6639 (Control #239123) Mild-CONTAIN CiclesOnide cliNical TriAl CovId-19 treatmeNt NCT04435795 | | Phase 2/3 Terminated Start date: 2020, September 14 Study termination date: 2021, July 8 | Experimental: Ciclesonide 50mcg intranasal BID and ciclesonide 600mcg 14 days Placebo comparator: Normal saline intranasal BID and Placebo 3 puff MDI inhaled BID | | Adult, COVID-19, symptomatic 215 participants | | Terminated (Could not meet target enrolment) | | Colchicine Montreal Heart Institute (2020-03-20) | | Phase Completed Start Date:2020, March 23 Study completion date: 2022, October 1 | | Experimental: Colchicine 0.5mg PO BID for 3 days, then once daily for the last 27 days. Placebo Comparator: Placebo PO BID for 3 days, then once daily for the last 27 days. | | Adults 40+, COVID-19 (within 24hrs), outpatient setting, must possess high-risk criteria (70 years or more of age, obesity (BMI 30 kg/m2), diabetes mellitus, uncontrolled hypertension (systolic blood pressure 150 mm Hg), known respiratory disease, known heart failure, known coronary disease, fever of 38.4\u00b0C within the last 48 hours, dyspnea at the time of presentation, bicytopenia, pancytopenia, or the combination of high neutrophil count and low lymphocyte count) 4488 participants (actual) | | Did not meet primary or secondary endpoints Tardif JC, et al. Colchicine for community-treated patients with (COLCORONA): a phase 3, double-blinded, | | PHRI.ACT.COVID19 (Control #238157) Anti-coronavirus therapies to prevent progression of COVID-19 (ACT), a randomized trial NCT04324463 | | Phase 3 Recruiting Start Date: 2020, April 21 Estimated study completion date: 2022, April 30 | | Outpatients Experimental: Colchicine 0.6mg PO BID for 3 days, then 0.6mg once daily for 25days Experimental: Aspirin (ASA) 75-100mg PO once daily for 28days intervention: Clinical standard of care Inpatients Experimental: Colchicine 1.2mg PO followed by 0.6mg PO 2 hours later, then 0.6mg PO BID for 28 days Experimental: Interferon Beta 0.25mg PO by subcutaneous injection on days 1,3,5, & 7 Experimental: Aspirin (ASA) 75-100mg once daily for 28days Experimental: Rivaroxaban 2.5mg PO BID for 28 days No intervention: Clinical standard of care | | Outpatient trial Adult, COVID-19 within 7 days of diagnosis or clinically worsening, high risk (age>70, male, obesity (BMI >30), chronic cardiovascular, respiratory or renal disease, active cancer, diabetes) Inpatient trial Adult, COVID-19, hospitalized (within 24hours or clinically worsening) 4000 participants | | Inpatient Colchine, rivaroxaban, and aspirin arms: Among patients hospitalised with COVID-19, neither colchicine nor the combination of rivaroxaban and aspirin prevent disease progression or death. Increased risk of gastrointestinal ADRs and bleeding.Eikelboom JW, Jolly SS, Belley-Cote EP, Whitlock Rangarajan S, Xu L, Heenan L, Luz Diaz Drapkina O, Felix C, Lopes RD, Berwanger O, Lopez-Jaramillo P, Anand SS, Bosch J, Choudhri S, Farkouh ME, Loeb M, Yusuf S. Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, Epub ahead of Other arms ongoing | | CPI-006 Corvus Pharmaceuticals Inc. (2021-03-01) | | CPI-006-003 (Control #249442) Authorized under the clinical trials interim order Phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care in mild to moderately symptomatic hospitalized COVID-19 patients NCT04734873 | | Phase 3 Terminated Start date: 2021, February 25 Termination date: 2021, August Experimental: CPI-006 2mg/kg or 1mg/kg Placebo comparator: Placebo | | 18+, hospitalized for COVID-19 46 participants | | Terminated (Sponsor decision. Not related to safety issues.) | | Dalcetrapid Dalcor Pharma UK Ltd (2020-11-26) | | DAL-401 (Control #246298) Authorized under Clinical Trial Interim Order A double-blind, placebo-controlled phase 2A proof-of-concept trial of Dalcetrapid in patients with confirmed mild to moderate COVID-19 NCT04676867 | | Phase 2 Completed Start date: 2021, January 11 Study completion date: 2021, May 17 | | Experimental: Dalcetrapid 900mg PO for 10 days, or 1800mg PO for 10 days, or 3600mg PO for 10 days Placebo comparator: Placebo PO for 10 days | | 18+, SARS-CoV-2 positive, COVID-19 symptomatic, outpatient 208 participants | | No benefit | | Dapagliflozin Saint Luke's Hospital of Kansas City (2020-07-04) | | D1690C00081 (Control #240352) Authorized under clinical trials interim order An international, multicenter, randomized, double-blind, placebo-controlled, Phase III study evaluating the efficacy and safety of dapaglifozin in respiratory failure in patients with COVID-19 (Dapagliflozin in respiratory failure in patients with COVID-19 (DARE-19)) NCT04350593 | | Phase 3 Completed Start date: 2020, April 22 Study completion date: 2021, June 11 | | Experimental: Dapagliflozin 10mg daily Placebo Comparator: Placebo 10mg daily | | Adult, mild-moderate COVID-19 (cannot be ventilated), hospitalized (no more than 4 days prior to screening), high risk (medical history of hypertension, T2DM, atherosclerotic cardiovascular disease, heart failure, or CKD stage 3 or 4 (eGFR 25-60mL/min.1,72m2)) 1250 participants (actual) | | In patients with cardiometabolic risk factors who were hospitalised with COVID-19, treatment with dapagliflozin did not result in a statistically significant risk reduction in organ dysfunction or death, or improvement in clinical recovery, but was well tolerated | | Dapsone Research Institute of McGill University Health Centre (2020-08-20) | | PDC01 (Control #242430) A randomized, placebo-controlled, multicenter study to assess the safety & efficacy of dapsone on the treatment of COVID-19 positive patients (DAP-CORONA) NCT04935476 | | Phase 3 Recruiting Start date: 2021, November 22 Estimated study completion date: 2022, July 31 | | Experimental: Dapsone 85mg PO BID for 21 days Placebo comparator: Placebo PO BID for 21 days | | Adult 40+, COVID-19 with symptom onset within the last 4 days, outpatient, high risk (at least 1 comorbidity) 3000 participants | | No results yet posted | | Dexamethasone University Health Network (2023-02-07) | | OZUHN-004 / control# 271810 Platform Of Randomized Adaptive Clinical Trial in Critical Illness (PRACTICAL) Randomized Control Trial | | EB05 Edesa Biotech Research Incorporated (2020-06-12) | | EB05-04-2020 (Control #239462) CTA issued under CT interim order A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EB05 + standard of care (SOC) vs. placebo + SOC in adult hospitalized patients with moderate to severe COVID-19 pneumonia NCT04401475 | | Phase 2/3 Recruiting Start Date: 2020, November 25 Estimated study completion date: 2021, April | | Experimental: EB05 15mg/kg IV (single infusion) + clinical standard of care Placebo comparator: Placebo IV (single infusion) + clinical standard of care | | Adult, COVID-19, Hospitalized, requiring supplemental oxygen 396 participants | | No results yet posted | | EMVODODSTAT (PTC299) PTC Therapeutics Inc. (2022-02-02)) | | PTC299-VIR-015-COV19 (Control # 260607) Evaluation of the efficacy and safety of PTC299 in hospitalized subjects with covid-19 (FITE19) NCT04439071 | | Phase 2/3 Terminated Start date: 2020, July 9 Termination date: 2022, July 20 | | Experimental: PTC299 200mg PO BID on Days 1 to 7, then 50mg PO QD on Days 8 to 14 + standard of care (SOC) Placebo comparator: matching placebo + SOC | | 18+, hospitalized, SARS-CoV-2 positive 189 participants | | Terminated (Sponsor decision) | | Favipiravir Appili Therapeutics Inc. (2020-05-18) | | CONTROL-COVID-Favipiravir-1 (Control #239133) Control of COVID-19 outbreak in long term care NCT04448119 | | Phase 2 Terminated Start date: 2020, October 16 Termination date: 2021, October 30 | | Experimental: (Prophylaxis) Favipiravir 1600mg (8 x 200mg tablets) PO BID on Day 1, followed by 800mg PO BID on Days 2-25 Experimental: (Treatment) Favipiravir 2000mg PO BID on Day1, followed by 1000mg PO BID for 13 days Placebo comparator: (Prophylaxis) Placebo 8 tablets PO BID on Day 1, followed by 4 tablets PO BID on Days 2-25 Placebo comparator: (Treatment) Placebo 10 tablets PO BID on Day 1, followed by 5 tablets PO BID for 13 days | | Adult 65+, long-term care resident, COVID-19 outbreak declared in one nursing unit 67 participants | | Terminated (Recruitment challenges) | | Favipiravir Appili Therapeutics Inc. (2020-11-02) | | double-blinded, placebo-controlled, randomized, multinational, phase-3 clinical trial to evaluate the efficacy of favipiravir in preventing the development of COVID-19 when given to asymptomatic SARS-CoV2-negative individuals who had direct exposure to a SARS-CoV2 infected person | | Phase 3 | | Experimental: Placebo comparator: | | Fenretinide (LAU-7B) Laurent (Control #238614) A double-blind, randomized, placebo-controlled, pilot phase II study of the efficacy and safety of Lau-7B in the treatment of adult hospitalized patients with COVID-19 disease (RESOLUTION) NCT04417257 | | Phase 2/3 Recruiting Start date: 2020, June 29 Estimated study completion date: 2023, April | | Experimental: LAU-7b PO QD for up to 14 days Placebo Comparator: Placebo PO QD for up to 14 days | | 45+, COVID-19, must have a comorbidity (diabetes, cardiovascular disease (including hypertension), respiratory disease (COPD, asthma, emphysema), smoker with 20-pack year history, Obesity, 70+, elevated troponin, or elevated CRP), hospitalized (or under observation) 508 participants | | In the overall moderate-to-critical patient population, LAU-7b did not meet its primary endpoint. However, in the moderate-to-severe COVID-19 patient subgroup LAU-7b + standard of care reduced the risk of death and progressing to mechanical ventilation by Day 60. BUT trial expanded to a Phase 3 trial. Results not posted. | | Fluvoxamine Research Institute of McGill University Health Centre (2020-11-30) | | 2021-7362 (Control #246471) Fluvoxamine for early treatment of COVID-19: A randomized placebo controlled trial (STOP COVID 2 Canada) NCT04668950 | | Phase 3 Completed Start date: 2020, December 22 Completion date: 2021, September 28 | | Experimental: Fluvoxamine 50mg PO once, then 100mg BID (as tolerated) for 15 days Placebo comparator: Placebo 50mg PO once, then 100mg BID for 15 days | | 18+, SARS-CoV-2 positive, COVID-19 symptomatic, ambulatory/not hospitalized 683 particpants | | Was stopped for futility by a data safety monitoring board after lower than expected case rates and treatment effect were observed | | Fondaparinux/ Tinzaparin Sodium (Innohep)/Dalteparin sodium (Fragmin)/Enoxaprin sodium (Lovenox)/Lovenox HP/Heparin (Therapeutic Unity Health (2020-04-24) | RAPID COVID COAG (Control #238510) Coagulopathy of COVID-19: A pragmatic randomized controlled trial therapeutic anticoagulation versus standard care as a rapid response to the COVID-19 pandemic (RAPID COVID COAG) NCT04362085 | | Phase 3 Completed Start Date: 2020, May 11 Study completion date: 2021, October 14 | | Experimental: Therapeutic anticoagulation (LMWH or UFH at clinician's discretion) administered in hospital until discharged, for 28 days, or death. No Intervention: Clinical standard of care | | Adult, COVID-19, hospitalized, one D-dimer value above ULN (within 72hrs of hospital admission) and either, D-dimer or D-dimer above ULN and oxygen saturation <93% 462 participants | | Therapeutic heparin was not significantly associated with a reduction in the primary composite outcome but the odds of death at 28 days was decreased | | Furosemide Kingston Health Science Centre (2010-10-13)) | | FAST-1 (Control #244310) filed under the IO) Nebulized furosemide for pulmonary inflammation in intubated patients with COVID-19- A phase 2/3 study NCT04588792 | | Phase 2/3 Recruiting Start date: 2021, April 16 Estimated study completion date: 2023, March 15 | | Experimental: Furosemide 40mg nebulization over Placebo nebulization QID for 28days | | Adult (18+), COVID-19, on mechanical ventilation 640 participants | | No results posted | | GS-5245 (Remdesivir prodrug) Gilead Sciences Canada Inc. (2022-09-20) | | GS-US-611-6273 / control # 267297 A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5245 for the treatment of COVID-19 in participants with high-risk for disease progression | | Phase 3 | | GSK3196165 (Otilimab), monoclonal antibody GlaxoSmithKline A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of otilimab IV in patients with severe COVID-19 related disease NCT04376684 | | Phase 2 Completed Start date: 2020, May 28 Study completion date: 2021, August 16 | | Experimental: Otilimab IV (single dose) + clinical standard of care Placebo Comparator: Placebo (0.9% sodium chloride solution) IV (single dose) + clinical standard of care | | Adult 18-79 years, COVID-19, hospitalized due to pneumonia, needing oxygen, have elevated markers of systemic inflammation (C-reactive protein > ULN or serum ferritin > ULN) 1156 participants | | Did not meet its primary end-point. However, patients 70 years and older in the otilimab + standard of care arm were less likely to experience respiratory failure 28 days after treatment and had reduced mortality up to Day 60. | | Hydroxychloroquine St. Joseph's Health Care Parkwood site (2020-05-09) | | 115769 (Control Safety and efficacy of post-exposure prophylaxis with hydroxychloroquine (HCQ) for the prevention of Corona Virus Infectious Disease-19 (COVID-19) in high-risk patients/residents in institutions NCT04397328 | | Phase 3 Withdrawn | | Experimental: Hydroxychloroquine 400mg PO, followed by 400mg in 8 hours, then 200mg BID for 4 days Placebo Comparator: Matched placebo doses tablets PO | | >40 years with one or more high risk comorbidities or >60 years, patient/resident of long-term care or other institute, exposed to a known or suspected COVID-19 case 336 participants | | Withdrawn | | Hydroxychloroquine Research Institute of the McGill University Health Centre (2020-03-25) | | COVID19 PEP PCT - Canada 2020-6549 (Control #237355) Post-exposure prophylaxis or preemptive therapy for SARS-Coronavirus-2: A pragmatic randomized clinical trial (COVID19 PEP RCT - Canada) NCT04308668 | | Phase 3 Completed Start Date: 2020, March 17 Study completion date: 2020, May 20 | | Experimental: Hydroxychloroquine 800mg (4 x 200mg tablets) PO, followed by 600mg 6-8hrs later, then 600mg QD for 4 days Placebo Comparator: Placebo 4 tablets PO, followed by 3 tablets 6-8hrs later, then 3 tablets QD for 4 days | | Adult, COVID-19 exposure within 4 days, COVID-19 within 4 days, outpatient at time of exposure 1309 participants (Actual) | | After high-risk or moderate-risk exposure to COVID-19, hydroxychloroquine did not prevent illness compatible with COVID-19 or confirmed infection when used as a postexposure prophylaxis within 4 days after exposure | | Hydroxychloroquine University Health Network (2020-04-03) | | HEROS-1 (Control #237851) Protecting frontline health care workers from COVID-19 with hydroxychloroquine pre-exposure prophylaxis: A randomized, placebo-controlled multi-site trial in Toronto, Canada NCT04374942 | | Phase 3 Terminated Start Date:2020, April 30 Termination date: 2021, April 29 | | Experimental: Hydroxychloroquine 400mg QD for 3 months Placebo Comparator: Placebo QD for 3 months | | Adult, health care worker in the emergency department 13 participants | | Terminated (Due to unproven issues associated with hydroxychloroquine use and safety, further complicated by media and political misinformation which in effect rendered all global studies on HCQ to stop enrolling participants.) | | Hydroxychloroquine University of Calgary (2020-04-09) | | HOPE ABCOV-01 (Control #237739) A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of oral hydroxychloroquine for the treatment of SARS-CoV-2 positive patients for the prevention of severe COVID-19 disease (ALBERTA HOPE COVID-19) NCT04329611 | | Phase 3 Terminated Start Date: 2020, April 13 Termination date: 2020, May 22 | | Experimental: Hydroxychloroquine 400mg PO BID for 1 day, followed by 200mg PO BID for 4 days Placebo Comparator: Placebo PO BID for 1 day, followed by PO BID for 4 days | | Adult, COVID-19 within 4 days 148 participants (actual) | | Terminated (Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack of Covid19 cases.) | | Hydroxychloroquine Research Institute of the McGill University Health Centre (2020-05-04) | | MP-37-2021-6659 (Control #238811) A multi-centre, randomized, blinded, placebo controlled clinical trial of the safety and effectiveness of hydroxychloroquine for the treatment of COVID-19 in hospitalized children | | Hydroxychloroquine University of Manitoba (2020-05-08) | | PREP2020 (Control #238396) prophylaxis for SARS-Coronavirus-2: A pragmatic randomized clinical trial NCT04308668 | | Phase 3 Completed Start date:2020, March 17 Study completion date: 2020, May 20 | | Experimental: Hydroxychloroquine 800mg PO, followed by 600mg in 6-8hours, then 600mg BID for 4 days Placebo comparator: Matching placebo tablets PO | | 18+, COVID19 or exposure to a COVID19 case 1309 participants (actual) | | After high-risk or moderate-risk exposure to COVID-19, hydroxychloroquine did not prevent illness compatible with COVID-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure | | Hyperpolarized Xenon-129 St. Joseph's Healthcare Hamilton (2020-11-05) | | FIRH_XE006 (Control #245507) Lung structure-function in survivors of mild and severe COVID19 infection: 129XE MRI and CT for rapid evaluations and next wave healthcare planning | | Hyperpolarized Xenon-129 Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University (2020-11-27) | | ROB0050 (Control #246389) Lung structure-function in survivors of mild and severe COVID19 infection: 129XE MRI and CT for rapid evaluations and next wave healthcare NCT04584671 | | Not yet recruiting Study start date: 2020, December (estimated) Estimated study completion date: 2024, December | | 18-80, SARS-CoV-2 positive 200 participants | | Not yet posted | | Hyperpolarized Xenon-129 The Hospital for Sick Children (2021-04-29) | | 1000074027 (Control #251634) Lung structure-function in survivors of mild and severe COVID19 infection: 129XE MRI for rapid evaluation and nextwave healthcare planning (LIVECOVIDFREE) | | Icosapent ethyl (Vascepa) Canadian Medical and Surgical Knowledge Translation Research (2020-05-08) | | VASCEPA-COVID-19 CARDIOLINK-9 (Control #239025) An investigation on the effects of icosapent ethyl (Vascepa) on inflammatory biomarkers in individuals with COVID-19 cardiolink-9 NCT04412018 | | Phase 2 Completed Start date: 2020, June 4 Completion date: 2020, December 12 | | Experimental: Icosapent Ethyl 4g BID for 3 days, then 2g BID for 11 days No intervention: Clinical standard of care | | 18-75 years, COVID-19, symptomatic, out-patient 100 participants | | Evidence of an early anti-inflammatory effect of icosapent ethyl in a modest sample, including an initial well-tolerated loading dose, in symptomatic outpatients with COVID-19. | | Tinzaparin sodium (Innohep)/enoxaparin sodium (Lovenox)/dalteparin sodium (Fragmin)/Heparin Sodium University (2020-04-29) | | OZM-113 (Control #238691) Therapeutic-dose anti-coagulation for the treatment of hospitalized patients with COVID-19: the antithrombotic therapy to ameliorate complications of COVID19 (ATTACC) trial NCT04372589 | | Phase 2/3 Completed Start Date: 2020, May 20 Study completion date: 2021, May 17 | | Experimental: LMWHeparin (preferably enoxaparin (SQ) QD) or dalteparin (200IU/kg SQ BID), 3rd option is unfractionated heparin (dependant on availability) for 14 days, until hospital discharge, or liberation of oxygen >24hrs) No intervention: Clinical standard or care (including usual thromboprophylactic dose anticoagulation according to local practice) | | Adults, COVID-19, Hospitalized (enrolled in study <72hrs since hospital admission and expected to remain in hospital >72hrs), not receiving mechanical ventilation 1200 participants (actual) | | In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis (No benefit in critically ill patients) | | Isoflurane, sevoflurane Sunnybrook Health Sciences Centre (2020-06-10) | | 2149 (Control #240138) Authorized under Clinical Trials Interim Order Sedating and volatile anesthetics critically ill COVID-19 patients in ICU: Effects on ventilatory parameters and survival; Multicentre open-label, pragmatic, randomised controlled trial and a parallel prospective (non-randomised) cohort study (SAVE-ICU) NCT04415060 | | Phase 3 Recruiting Start Date: 2020, June 15 Estimated study completion date: 2023, June 15 | | Experimental: Isoflurane inhalant product (either Isoflurane or Sevoflurane depending on availability) dosage is based on clinical judgement No intervention: Clinical standard of care (IV sedation) | | Adults, COVID-19, mechanically ventilated <48hrs 752 participants | | No results posted | | Ifenprodil (NP-120) Algernon Pharmaceuticals (2020-04-29) | | AGN120-3 (Control #238605) A randomized open label Phase 2/3 study of the safety and efficacy of NP-120 (Ifenprodil) for the treatment of confirmed COVID-19 Infected hospitalized patients NCT04382924 | | Phase 2/3 Completed Start Date: 2020, August 5 Completion date: 2021, January Intervention: Clinical standard of care | | Adult, COVID-19, hospitalized, requiring oxygen or non-invasive ventilation, 168 participants | | No benefit, terminated | | Ixekizumab (Taltz)/ Apremilast tablets (Otezla)/ Lanadelumab/ | | COV-01 (control #242568) Authorized under the clinical trials interim order Industry alliance platform trial to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalized patients NCT04590586 | | Phase 3 Completed Start Date: 2020, November 24 Completion date: 2021, August 3 | | Experimental: Apremilast PO + standard of care (SOC) Experimental: Lanadelumab IV + SOC Experimental: Zilucoplan SC + SOC Placebo comparator: Matching placebo PO | | Adult (18+), COVID-19, Hospitalized 516 participants | | Terminated | | Lopinavir/ritonavir Unity Health Toronto (2020-03-21) | | CORIPREV-1 (Control #237350) COVID-19 ring-based prevention trial with lopinavir/ritonavir (CORIPREV-LR) NCT04321174 | | Phase 3 Active, not recruiting Start Date: 2020, April 17 Estimated study completion date: 2022, March 31 | | Experimental: Lopinavir/ritonavir 400/100mg PO BID for 14 days No intervention: Clinical standard of care | | >6months of age, High-risk close contact with a confirmed COVID-19 case during their symptomatic period (including one day before symptom onset), with the past 1-7days 123 participants | | No results posted | | Interferon beta-1a, apo-hydoxyquine, Heparin sodium, Lovenox, recovered COVID-19 patients (convalescent plasma), Kineret, Vitamin C Unity Health Toronto (2020-04-01) | | REMAP-CAP X17-0199 (Control #237719) Randomized, embedded, platform trial for community-acquired pneumonia (REMAP-CAP): Pandemic appendix to the core protocol NCT02735707 | | Phase 4 Recruiting Start Date: 2016, April 11 Estimated study completion date: 2023, December | | Experimental: Hydrocortisone 50mg IV q6hrs for up to 7days No intervention: clinical standard of care but no systemic corticosteroid Experimental: Hydrocortisone 50mg IV q6hrs (when in septic shock) Experimental: Ceftriaxone + Macrolide (dose and duration according to local practice guidelines) Experimental: Moxifloxacin + Levofloxacin (according to local practice guidelines) Experimental: Piperacillin-tazobactam + Macrolide (according to local practice guidelines) Experimental: Ceftaroline + Macrolide (according to local practice guidelines) Experimental: Amoxicillin-clavulanate + Macrolide (according to local practice guidelines) Experimental: (nested within other antibiotic arms) Macrolide (azithromycin is preferred but clarithromycin or roxithromycin are possible substitutes) for 3 to 5 days Experimental: (nested within other antibiotic arms) Macrolide (azithromycin is preferred but clarithromycin or roxithromycin are possible substitutes) for 14 days or at hospital discharge No Intervention: clinical standard of care but no antiviral agent active against influenza Experimental: Oseltamivir PO BID for 5 days or at hospital discharge Experimental: Oseltamivir PO BID for 10 days or at hospital discharge No intervention: clinical standard of care but no antiviral against SARS-CoV-2 Experimental: Lopinavir/ritonavir 400/100mg PO or 5mL 80/20mg/mL solution suspension via gastric tube q12hrs for 5-14 days (depending on hospital discharge) Experimental: Hydroxychloroquine 800mg PO q6hrs for two doses then 400mg q6hrs for 12 doses or until hospital discharge Experimental: Hydroxychloroquine 800mg PO q6hrs for two doses then 400mg q6hrs for 12 doses or until hospital discharge + lopinavir/ritonavir 400/100mg PO or 5mL 80/20mg/mL solution suspension via gastric tube q12hrs for 5-14 days (depending on hospital discharge) No Intervention: Clinical standard of care but no immune modulating therapy Experimental: Interferon-Beta1a 10ug IV QD for dose) Experimental: Sarilumab 400mg IV (single dose) No intervention: clinical standard of care but no vitamin C Experimental: Vitamin C 500mg/kg IV q6hrs for 16 doses No intervention: clinical standard or care + local standard care thromboprophylaxis for 14 days Experimental: LMWHeparin or UF Heparin IV (to achieve systemic anticoagulation according to local practice) No Intervention: Standard care but no simvastatin for up to 28 days while hospitalized Experimental: Simvastatin 80mg PO QD while hospitalized No Intervention: standard care but no immunoglobulin during hospitalization Experimental: ABO convalescent plasma (no more than 2 units) No intervention: standard of care + invasive mechanical ventilation (according to local practice) Experimental: Invasive mechanical ventilation (protocolized strategy) | | Adult, ICU admitted within 48hrs of hospitalization, severe community acquired pneumonia (CAP) and/or suspected or proven COVID19, lower respiratory tract infection, radiological evidence of new onset consolidation, requiring ventilation, receiving infusion of vasopressor and/or inotropes 7100 participants | | Corticosteroid domain was halted after results were released from another trial. Follow-up ended August 12, 2020. Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Results from other arms of the trial have not been posted | | Losartan Providence Health Care Saint Paul's Hospital (2020-09-28) | | ARBS CORONA II (Control # 243532) Authorized under the Interim Order Host response mediators in coronavirus (COVID-19) infection - Is there a protective effect of losartan on outcomes of coronavirus infection? NCT04606563 | | Phase 3 Terminated Start date: 2020, October 9 Termination date: 2022, April 22 | | Experimental: Losartan 25mg PO, stepped up to 50mg and then up to 100mg, as tolerated, q24hrs for length of hospital stay (max 3 months) No intervention: clinical standard of care | | Adult (18+), COVID-19, hospitalized 341 participants | | Terminated (DSMC recommendation due to futility) | | LSALT Peptide Arch Biopartners Inc. (2020-05-07) | | AB002 (Control #238815) Multi centre, randomized, double-blind, placebo controlled, proof of concept trial of LSALT PEPTIDE as prevention of acute respiratory distress syndrome (ARDS) in patients infected with SARS-CoV-2 (COVID-19) NCT04402957 | | Phase 2 Active, not recruiting Start Date: 2020, July 1 Estimated study completion date: 2021, June 30 | | IV QD | | 45-80 years old, moderate to severe COVID-19, hospitalized, APACHE II score <20 60 participants | | Company's press release reports potential benefit and no ADRs. Trial is being expanded. Peer reviewed report not yet available. | | MK-4482 (molnupiravir) Merck Canada Inc. (2020-10-19) | | MK-4482-001 (Control #244315) filed under the interim order A phase 2/3 randomized, placebo controlled, double-blind clinical study to evaluate the efficacy, safety and pharmacokinetics of MK-4482 in hospitalized adults with COVID-19 NCT04575584 | | Phase 2/3 Terminated Start Date: 2020, October 19 Study termination date: 2021, August 11 | | Experimental Part 1: Molnupiravir 200mg PO q12hrs for 5 days Experimental Part 1: Molnupiravir 400mg PO q12hrs for 5 days Experimental Part 1: Molnupiravir 800mg PO q12hrs for 5 days Experimental Part 2: Molnupiravir (dose TBD) PO q12hrs for 5 days Placebo comparator: Placebo matching tablet PO q12hrs for 5 days | | Adult (18+), mild-moderate COVID-19 for under 7 days 304 participants | | Terminated (Business reasons) | | MK-4482 (molnupiravir) Merck Canada Inc. (2020-10-19) | | MK-4482-002 (Control #244159) filed under the interim order A phase 2/3 randomized, placebo controlled, double-blind clinical study to evaluate the efficacy, safety and pharmacokinetics of MK-4482 in non-hospitalized adults with COVID-19 NCT04575597 | | Phase 2/3 Completed Start Date: 2020, October 19 Estimated study completion date: 2022, May 5 | | Experimental Part 1: Molnupiravir 200mg PO q12hrs for 5 days Experimental Part 1: Molnupiravir 400mg PO q12hrs for 5 days Experimental Part 1: Molnupiravir 800mg PO q12hrs for 5 days Experimental Part 2: Molnupiravir (dose TBD) PO q12hrs for 5 days Placebo comparator: Placebo matching tablet PO q12hrs for 5 days | | Adult (18+), mild-moderate COVID-19 for under 7 days 1734 participants | | Jayk Bernal A, Gomes da Reyes V, Mart\u00edn-Quir\u00f3s Caraco Y, Williams-Diaz A, Brown Du J, A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, A, Butterton JR, Johnson MG, De Anda C; MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N J Med. A, Moncada PA, Burgess L, Duke ER, Ohmagari N, Wolf T, Bassetti M, Bhagani S, Ghosn J, Zhang Y, Wan H, Williams-Diaz A, Brown ML, Paschke A, De Anda C. Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial. Ann Intern Med. 2022 Naltrexone British Columbia Women's hospital (2022-06-01) | | H21-02254 Control # 263975 A double blind randomized trial for low-dose naltrexone for post-covid fatigue syndrome NCT05430152 | | Phase 2 Not yet recruiting Estimated start date: 2023, March Estimated completion date: 2024, February | | Experimental: 1mg Naltrexone (low dose) titrated up by 1mg/week until max dose of 4.5mg for 16 weeks. Placebo comparator | | 19+, Confirmed past SARS-CoV-2 positive, persistent synptoms of fatigue post-viral infection (PVI) (Long-COVID/post-COVID syndrome)s 60 participants | | No results posted | | Nirmaltrelvir (PF-07321332) / Ritonavir (Paxlovid) Pfizer Canada ULC (2022-08-02) | | C4671034 Control # 265231 An interventional efficacy and safety, phase 2, randomized, double-blind, 3 arm study to investigate nirmatrelvir/ritonavir in non-hospitalized particicpants at least 12 years of age with symptomatic covid 19 who are immunocompromised NCT05438602 | | Phase 2 Recruiting Start date: 2022, August 3 Estimated completion date: 2023, November 13 | | Experimental: 300mg Nirmaltrelvir BID for 5 days + 100mg Ritonavir BID for 10 days Experimental: 300mg Nirmaltrelvir BID for 10 days + 100mg Ritonavir 5 days Experimental: 300mg Nirmaltrelvir BID + 100mg Ritonavir BID for 15 days Placebo comparator | | 12 years +, SARS-CoV-2 positive, immunocompromised 200 participants | | No results posted | | Nirmaltrelvir (PF-07321332) / Ritonavir (Paxlovid) C4671042 /control # 268341 An interventional, efficacy and safety, phase 2, randomized, double-blind, 2-arm study to investigate a repeat 5-day course of nirmatrelvir/ritonavir compared to placebo/ritonavir in participants at least 12 years of age with rebound of COVID-19 symptoms and rapid antigen test positivity NCT05567952 | | Phase 2 Recruiting Start date: 2022, October 19 Estimated completion date: 2023, November 28 | | Experimental: Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) PO BID for 5 days Comparator: placebo (2 tablets) plus ritonavir (1 capsule) PO BID for 5 days | | 12 + years, Documentation of nirmatrelvir/ritonavir treatment with patient-reported 100% compliance. Symptom alleviation or resolution in COVID-19 signs/symptoms followed by a worsening (rebound) of signs/symptoms after completing an initial 5-day course of nirmatrelvir/ritonavir 411 participants | | No results posted | | Nirmaltrelvir/ Ritonavir (Paxlovid) Unity Health Toronto (2022-11-02) | | CANTREATCOVID-1 / control # 269011 (Authorized under the COVID-19 Regulations) Canadian adaptive platform trials of treatments for COVID in Community Settings (CanTreatCOVID) NCT05614349 | | Phase 3 Recruiting Start date: 2023, January 16 Estimated completion date: 2025, January | | Experimental: Nirmatrelvir/ritonavir (Paxlovid) BD x 5 days No Intervention: Control group - Usual care (i.e., supportive care and symptom relief) Experimental: Other Emerging Interventions (Additional treatment regimens will be decided by the Canadian COVID-19 Out-Patient Therapeutics Committee based on doses and durations studied in past trials and the latest evidence) | | 18 +, SARS-CoV-2 positive, outpatient, 1 or more chronic high risk medical condition 12000 participants | | No results posted | | Nitric oxide University Health Network (2020-06-25) | | 20-5449 (Control # 239579) Use of high dose inhaled nitric oxide in intubated patients admitted with COVID-19 NCT04383002 | | Phase 1 Completed Start Date: 2020, September 2 Estimated study completion date: 2021, June 11 | | Experimental: Nitric Oxide 160ppm for 6 hours (inhaled) QD for 2 days No Intervention: Clinical standard of care | | Adult, COVID-19 (<14 days from symptom onset), mechanical ventilation (<7 days from intubation) 20 participants | | No results posted | | Nitric Oxide Beyond Air Inc. (2020-05-19) | | BAI_COV19_01 (control #239071) Inhaled NO for the treatment of COVID-19 caused by SARS-CoV-2 NCT04397692 | | Phase N/A Terminated Start Date: 2020, June 13 Termination date: 2020, September 30 | | Experimental: Nitric Oxide 80ppm inhaled via LungFit system QID No intervention: Clinical standard of care | | 22-65 years, COVID-19, Hospitalized (within 24hrs), oxygen saturation <93%, shortness of breath (onset within previous 8 days) 4 participants | | Terminated (Slow recruitment) | | Nitric Oxide Sanotize Research & Development Corp (2020-04-18) | | COVID-CTP-01 (Control #237786) Multi-center, randomized, controlled, phase II clinical efficacy study evaluating NORS treatment for the prevention and treatment of COVID-19 in Healthcare workers & individuals at risk of infection NCT04337918 | | Phase 2 Completed Start date: 2020, May 8 Study completion date: 2021, February 2 | | Experimental: Nitric Oxide (NO) gargle every morning, NO nasopharyngeal irrigation every evening, and NO Nasal spray up to 5times a day for 14 days No Intervention: clinical standard of care | | Adult >19years, work/live with COVID-19 infected patients, COVID-19 negative, COVID-19 positive (sub-study) 143 participants (actual) | | Nobody from the treatment arm got infected and strong safety data was shown (but peer-reviewed publication is not available) | | Nitric Oxide Sanotize Research & Development Corp. (2020-06-30) | | COVID-CTP-02 (Control #240702) Multi-center, double-blinded placebo-controlled, phase II clinical efficacy study evaluating NORS to treat and prevent the exacerbation of infection in individuals with documented mild COVID-19 NCT04443868 | | Phase 2 Withdrawn (no subjects enrolled) | | Experimental: Nitric oxide-releasing drug Nasal spray + Nasal Irrigation Placebo Comparator: Placebo | | Adult, mild COVID-19 no flu-like symptoms 0 participants | | Withdrawn (no subjects enrolled) | | Nitric Oxide Sanotize Research & Development Corp. (2021-05-14) | | COVID-NONS-04 (Control #252244) Decentralized, randomized, double-blinded, placebo-controlled, phase 3 clinical efficacy study evaluating nitric oxide nasal spray (NONS) as prevention for treatment of individuals at risk of exposure to COVID-19 infection NCT05109611 | | Phase 3 Active, not recruiting Start date: 2021, November 20 Estimated study date: 2023, July 30 | | Experimental: Nitric oxide releasing solution (NORS) nasal spray up to 3 times daily Placebo comparator | | 18+, healthy (or stable chronic condition) 1389 participants | | Not posted | | Nitric Oxide Sanotize Research & Development Corp. (2021-05-25) | | COVID-NONS-05 (Control #252713) Multi-center, double-blinded, placebo-controlled parallel, phase 3 clinical efficacy study evaluating nitric oxide nasal spray (NONS) to treat and prevent the exacerbation of infection in individuals with documented mild COVID-19 | | Phase 3 | | Nitric Oxide Dr. Jeremy Road (2020-03-19) | | NTM-CTP-01 (Control #236728) An open label safety study of inhaled gaseous nitric oxide (gNO) for adults & adolescents with non-tuberculous mycobacteria NCT03331445 | | Phase 2 Terminated Start Date: 2017, October 24 Study termination date: 2021, June | Experimental: Nitric oxide 0.5%/Nitrogen 99.5% (gas) 160ppm inhaled | | COVID-19 SubStudy- Adult, COVID-19 (within 5 days), Original inclusion criteria - previously diagnosed with NTM, Burkholderia app, Aspergillus spp., or corona-like viral infection, > 14years, able to breath without supplemental oxygen, non-smoker 13 participants | | Terminated (COVID incidence too low and funding completed) | | Nitric Oxide St. Paul's Hospital Vancouver (2021-01-15) | | COVID-NORS-01 (Control #247971) The efficacy of topical nitric oxide releasing solutions (NORS) in the management of coronavirus disease 2019 (COVID-19) | | Omalizumab (Xolair) The Research Institute of the McGill University Health Centre (2020-12-21) | | CIAO_COVID20 (control #246983) COVID-19 immunologic antiviral therapy with omalizumab (CIAO trial) - An adaptive Phase II randomized-controlled clinical trial NCT04720612 | | Phase 2 Active, not recruiting Study start date: 2021, October 15 Estimate study completion date: 2022, December 16 | | Experimental: Omalizumab 375mg Placebo subcutaneous dose | | 18+, SARS-CoV-2 positive, hospitalized 40 participants | | Results not posted | | Oxygen Ottawa Hospital Research Institute (2020-07-30) | | OHRI-HBOT-001 Multicentre randomized controlled trial of hyperbaric versus normobaric oxygen therapy for COVID-19 patients NCT04500626 | | Phase 2/3 Recruiting Start Date: 2021, April 15 Estimated study completion date: 2022, August | Experimental: Hyperbaric oxygen therapy (HBOT) 75mins No Intervention: standard of care (including normobaric oxygenation) | | Adult, COVID-19, pneumonia requiring oxygenation but not mechanical ventilation 234 participants | | No results posted | | Ozanimod Institut Universitaire de Cardiologie et de Pneumologie de Quebec (2020-07-13) | | NCT04405102 (Control #241148) A randomized trial on efficacy and safety of Ozanimod for the treatment of COVID-19 patients requiring oxygen support - a pilot trial (COZI) NCT04405102 | | Phase 2 Terminated Start Date: 2020, September 16 Termination date: 2022, May 12 | | Experimental: Ozanimod 0.23mg QD for 4 days followed by 0.46mg QD for 10 days No Intervention: standard of care | | 18-85 years, COVID-19, BMI 20-35, hospitalized requiring oxygen but not ventilation 43 participants | | Terminated (Screening was stopped by the Sponsor (43/48 participants enrolled), given the very low number of eligible patients (high vaccination rate and occurrence of the Omicron variant). The last patient randomized performed his follow-up visit.) | | Peginterferon Lambda-1A University Health Network (2020-04-29) | | JF-4-2020 (Control #238558) Interferon Lambda for immediate antiviral therapy at diagnosis (ILIAD): A phase II randomized, open-label, multicenter, trial to evaluate the effect of peginterferon lambda for the treatment of COVID-19 NCT04354259 | | Phase 2 Completed Start Date: 2020, May 13 Study completion date: 2021, February 5 | | Experimental: Peginterferon lambda dose) (ambulatory cohort) Experimental: Peginterferon lambda 180ug SC followed by a second dose on day 7 (hospitalized cohort) Placebo comparator: Sodium chloride 0.9% SC (one dose) | | Adult, COVID-19, at home (ambulatory cohort), hospitalized (hospitalized cohort) 140 participants | | Peginterferon lambda accelerated viral decline in outpatients with COVID-19, increasing the proportion of patients with viral clearance by day 7, particularly in those with high baseline viral load. Peginterferon lambda has potential to prevent clinical deterioration and shorten duration of viral shedding. | | Peginterferon Lambda-1A Dr. Jordan Feld, University Health Network, Toronto General Hospital (2021-01-13) | | JF-12-2020 (Control #247938) Interferon lambda therapy for symptomatic SARS-CoV-2 early in infection (ODYSSEY): A phase III randomized, double-blind, placebo-controlled, multicenter trial to evaluate the effect of peginterferon lambda for the treatment of COVID-19 NCT04967430 | | Phase 3 Active, not recruiting Start date: 2021, August 27 Estimated completion date: 2022, June 30 | | Experimental: Peginterferon lambda 180mcg SC, one dose Placebo comparator | | 18 +, SARS-CoV-2 positive, symptomatic, high risk of severe disease, discharged to home isolation 763 participants | | No results posted | | Pentoxifylline, Ibudilast (MN-166) University Health Network (2023-01-25 and 2023-02-03) | | OZUHN-002 / control # 271420 (Authorized under the COVID-19 Regulations) Recovering From COVID19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM) NCT05513560 | | Phase 2/3 Not yet recruiting Start Date: 2023, February (estimated) Study completion date: 2025, July Experimental: Ibudilast 20mg PO BID Pentoxifylline 400mg PO TID Placebo comparator | | 18+, past SARS-CoV-2 positive result, lingering COVID-19 symptoms after 3 months of COVID-19 onset, with persistent COVID-19 symptoms (at least 2 months), post COVID Condition/Long COVID 1000 participants | | No results posted | | Perflenapent (NanO2) Research Institute of the McGill University Health Centre (2020-06-10) | | EXTENDED-P2 (Control #240041) EXTENDED (Novel O Therapeutic NaNO2 for COVID-19 induced ARDS) EXTEND-P2 (Control #246808) Authorized under the clinical trials interim 1/2| | Polyriboinosinic | | ONV2020-003 (Control #243532) under the Interim Order A phase I-Ib, double-blinded, randomized repeated dose multicenter, nasal Poly-ICLC (Hiltonol) for prophylaxis of COVID-19 in healthy adults NCT04672291 | | Phase 1 Recruiting Start date: 2021, July 21 Estimated study completion date: 2023, January 31 | | Experimental: Poly-ICLC 2 cycles (safety cohort) Placebo: Placebo 2 cycles Experimental: Poly-ICLC 3 cyles (expansion cohort) Placebo: Placebo 3 cycles | | Adult, healthy 43 participants | | No results posted | | Prednisone Governors of the University of Alberta (2021-03-08) | | CORE-COVID (Control #249936) A randomized clinical trial comparing 7 days treatment with corticosteroids versus placebo for early COVID-19 NCT04795583 | | Phase 3 Withdrawn (Funding issue) | | Experimental: Prednisone 50mg/day (if less than 50kg), 75mg/day (if 50-80kg), or 100mg/day (if greater than 80kg) for 7 days Placebo comparator: Placebo capsules for 7 days | | 18+, SARS-CoV-2 positive 0 participants | | Withdrawn (Funding issue) | | Propranolol Ottawa Hospital Research Institute (2020-06-10) | | 776228483 PROACTIVE (Control #240296) Propanolol as an anxiolytic to reduce the use of sedatives for critically ill adults receiving mechanical ventilation: an open-label randomized controlled trial (PROACTIVE) NCT04467086 | | Phase 3 Completed Start Date: 2020, December 11 Study completion date: 2022, November 30 | | Experimental: Propranolol hydrochloride 20mg PO q6hrs for 2 doses, then 30mh q6hrs for 4 doses, 50mg q6hrs for 4 doses, 60mg q6hrs No intervention: clinical standard of care | | Adult (19+), ICU on mechanically ventilation 72 participants | | No results posted | | ProTrans (Wharton's Jelly derived Umbilical Cord Mesenchymal Stromal Cells (UCMSC)) Research Institute of the McGill University Health Centre (2020-10-16) | | 2021-6954 (CTA Control #244461) filed under the Interim Order Treatment of respiratory complications associated with COVID-19 infection using Wharton's Jelly (WJ)-umbilical cord (UC) mesenchymal stromal cells (ProTrans): a randomized phase II controlled clinical trial NCT04869397 | | Phase 2 Recruiting Start date: 2021, June 14 Estimated completion date: | Experimental: Allogeneic Wharton's jelly-MSCs (WJ-MSC) IV, one dose of 5 million cells/minute over 20 minutes Placebo comparator | | 18+, SARS-CoV-2 positive, hospitalized but not ventilated 48 participants | | Not posted | | Pulmozyme (Dornase Alfa, rhDNase1) The Research Institute of McGill University Health Centre (2020-07-24) | | DISCONNECT-1 CTA Control #241689 DISmentling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1): Phase I pilot study investigating the safety and feasibility of inhaled rhDNase1 and its impact on neutrophil extracellular traps (NETs) in non-ventilated COVID-19 infected patients NCT04409925 | | Phase 1 Unknown Start Date: 2020, December 25 Estimated study completion date: 2021, August | | Experimental: rhDNase1 (Pulmozyme) 2.5mg inhaled BID for a maximum of 14 days | | Adult, COVID-19, hospitalized on oxygen but not ventilation 25 participants | | No results posted | | Recombinant human alkaline phosphatase AM-PHARM A B.V parallel-group, multi-center Phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis associated acute kidney injury NCT04411472 | | Phase 3 Terminated Start Date: 2020, October 15 (estimated) Termination date: 2022, August 18 | | Experimental: recombinant human alkaline phosphatase 1.6mg/kg TID infusions Placebo comparator: matching placebo | | Adult, ICU or intermediate care unit, sepsis requiring vasopressor therapy 661 participants | | NTerminated (The Data Monitoring Committee (DMC) concluded that the pre-specified futility threshold was met and that there was no safety concern) | | Recombinant human annexin A5 (SY-005) Lawson Health Research Institute (2021-02-05) | | REDA-10122 (Control #248696) Authorized under the clinical trials interim order Annexin A5 in patients with severe COVID-19 disease NCT04748757 | | Phase 2 Recruiting Start date: 2021, April 20 Estimated study completion date: 2022, December | | Placebo comparator: Normal 7days (high dose) | | 19+, SARS-CoV-2 positive, admitted to ICU for organ failure support 60 participants | | Not yet posted | | Remdesivir Gilead Sciences Canada Inc. (2020-04-15) | | GS-US-540-5821 (Control #238163) Expanded access treatment the treatment of SARS-COV2 (COV) infection NCT04323761 | | No longer available | | Remdesivir, interferon beta-1a Sunnybrook Research Institute (2020-03-18) | | CATCO 2114 (Control #237108) The Canadian arm of the WHO SOLIDARITY trial. A multi-centre, adaptive, randomized, open-label, controlled clinical trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized patients NCT04330690 | | Phase 2 Recruiting Start Date: 2020, March 18 Estimated study completion date: 2024, May 18 | | Experimental: Lopinavir/ritonavir 400mg/100mg PO for 14 days or until hospital discharge Experimental: Hydroxychloroquine 800mg BID for 1 day, then 400mh BID for 10 days Experimental: Remdesivir 200mg IV on day 1, then 100mg IV QD for 9 days No Intervention: Clinical standard of care | | Adult, COVID-19, Hospitalized 2900 participants | | No results yet posted (although the lopinavir/ritonavir and hydroxychloroquine arms have been stopped) | | Remestemcel-L Mesoblast, Inc (2020-07-31) | | CTSN-MSC-ARDS001 (Control #241138) Mesenchymal stem cells for the treatment of moderate to severe COVID-19 acute respiratory distress syndrome NCT04371393 | | Phase 3 Terminated Start Date: 2020, April 30 Termination date: 2022, January 2 | | Experimental: Remestemcel-L 2x10^6 MSC/kg IV on day 1 and day 4 Placebo Comparator: Plasma-Lyte (placebo) on day 1 and day 4 | | Adult, COVID-19, ARDS, mechanical ventilated 223 participants | | Terminated (At 3d interim analysis, randomization, but not follow-up, was halted by the DSMB due to low predictive probability of achieving postulated mortality benefit (pre-specified 42.5% relative mortality reduction) were the trial to complete randomization.) | | Ribavirin (Virazole) 5401-HC (Control #238007) An open label study to evaluate the safety and efficacy of virazole (ribavirin for inhalation solution, USP) in hospitalized adult participants with respiratory distress due to COVID-19 NCT04356677 | | Phase 1 Withdrawn | | Experimental: Virazole 50mg/mL aerosolized BID up to 6 days Experimental: Virazole 100mg/mL aerosolized BID up to 6 days | | Adult, COVID-19, hospitalized 0 participants | | Withdrawn (Due to pandemic status changing in Canada prior to investigative sites being initiated for participation, and that concurrent participant recruitment in the global study BHC-RIB-5401-GL will achieve target enrollment across all countries) | | Ruxolitinib (Jakavi) Novartis Pharmaceuticals Canada Inc. (2020-06-16) Phase 3 randomized, double-blind, placebo-controlled, multi-centre study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID) NCT04362137 | | Phase 3 Completed Start Date: 2020, May 2 Study completion date: 2020, October 17 | | Experimental: Ruxolitinib 5mg PO BID for 14 days with possible extension to 28 days Placebo Comparator: Placebo PO BID for 14 days with possible extension to 28 days | | Age 12+, COVID-19, hospitalized, sign of decreased lung capacity or damage 432 participants (actual) | | Did not meet its primary ot secondary endpoints | | Ruxolitinib University Health Network (2020-04-07) | | U-DEPLOY (OZUHN-001/Sub protocol # OZUHN-001-2) (Control #237848) Umbrella trial defining coordinated approach to pandemic trials of COVID-19 and data harmonization to accelerate discovery (sub-study of the larger study) NCT04331665 | | Phase N/A Completed Start Date: 2020, May 21 Study completion date: 2021, March 24 | | Experimental: Ruxolitinib 10mg BID for 14 days, followed by 5mg BID for 2 days and 5mg QD for 1 day | | 12 years+, COVID-19, needing supplemental oxygen 3 participants | | Terminated | | Sarilumab (Kevzara) Sanofi-Aventis Canada Inc. (2020-03-24) | | An adaptive phase 2/3 randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 NCT04315298 | | Phase 2/3 Completed Start Date: 2020, March 18 Study completion date: 2020, September 2 | | Experimental: Sarilumab (low dose) IV Experimental: Sarilumab (mid dose) IV Experimental: Sarilumab (high dose) IV | | Adult, COVID-19, hospitalized, pneumonia, Phase 2: must have severe disease, critical disease, multi-system organ dysfunction, or immunocompromised, Phase 3: receiving mechanical ventilation 1912 participants (actual) | | Did not meet its primary or secondary endpoints | | Semaglutide (Ozempic) University Health Network (2020-10-07) | | UHNSEMPATICO1 (Control #244389) Semaglutide to reduce myocardial injury in patients with COVID-19 NCT04615871 | | Phase 2 Recruiting Start date: 2021, September 10 Estimated Study Completion date: 2022, March 31 | | Experimental: Semaglutide 0.25mg S.C., then 0.5mg on Day 7, Day 14, and Day 21 No intervention: Clinical standard of care | | Adult (18+), COVID-19, hospitalized, with two other high-risk features 400 participants | | No results posted | | Tocilizumab (Actemra) University of Calgary (2020-05-22) | | REB20-0713 (CTA Control # 239287) (A prospective, observational study) (A Nested Interventional Cohort Study) to assess the efficacy and safety of adjunctive humanized monoclonal Interleukin 6 receptor antibody Tocilizumab (TCZ) therapy to standard of care for the reduction of hyperinflammation related mortality in SARS-CoV-2 positive patients (Tocilizumab in Coronavirus-19 Positive Patients) NCT04423042 | | Phase 3 Unknown Start Date: 2020, July 30 (estimated) Estimated study completion date: 2021, June | | Experimental: Tocilizumab 8mg/kg IV up to a maximum of 800mg with a possible repetition of the same dose after 12hrs but within 28hrs No Intervention: Clinical Standard of Care | | Adult, COVID-19, experiencing hyperinflammation (Elevated C-reactive protein (>70mg/dl or raising over a 24h period), Ferritin (>700mcg/L or rising over a 24h period) 30 participants | | No results posted | | Tocilizumab (Actemra/RoActemra) Hoffman-La Roche Limited (2020-03-25) A randomised, double-blind, placebo-controlled, multicentre study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia) NCT04320615 | | Phase 3 Completed Start Date: 2020, April 3 Study completion date: 2020, July 28 | | Experimental: Tocilizumab (TCZ) 8mg/kg up to a maximum of 800mg IV (one additional dose may be added if clinical symptoms worsen or no improvement) Placebo Comparator: Placebo matched to TCZ dose IV | | Adult, COVID-19, hospitalized, pneumonia 450 participants (actual enrollment) | | CONVACTA did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortality Roche remains committed to continuing the Actemra/RoActemra clinical trial programme in COVID-19 to further explore Actemra/RoActemra in other treatment settings, including in combination with an antiviral | | Vitamin C Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (2020-06-05) | | LOVIT-COVID MP-31-2021-3741 Lessening Organ Dysfunction with VITamin C - COVID (LOVITCOVID) NCT04401150 | | Phase 3 Suspended Start Date: 2020, August 14 Estimated study completion date: 2022, December | | Experimental: Vitamin C 50mg/kg IV 96hrs (0.9% NaCl) IV q6hrs for 96hrs (16 doses) | | Adult, COVID-19, Hospitalized 800 participants | | Suspended (On July 15, 2022, the LOVIT-COVID DSMB was aware of the recommendation of the REMAP-CAP DSMB to cease enrollment into the Vitamin C domain of that trial. Given that, the LOVIT-COVID DSMB suggested pausing enrollment into LOVIT-COVID immediately.) | | Vitamin C (ascorbic acid) Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (2020-03-18) | | MP-31-2019-2945 (Control #237164) Lessening Organ Dysfunction with Vitamin C (LOVIT) NCT03680274 | | Phase 3 Completed Start Date: 2018, November 8 Completion date: 2022, January 24 | | Experimental: Vitamin C 50mg/kg IV q6hrs for 96hrs (16 (0.9% NaCl) IV q6hrs for 96hrs (16 doses) | | Adult, ICU with proven or suspected infection, being treated with IV infusion of vasopressors 872 participants | | Lamontagne F, Masse MH, Menard J, Sprague S, Pinto R, Heyland DK, Cook DJ, Battista MC, Day AG, Guyatt GH, Kanji S, Parke R, McGuinness SP, Tirupakuzhi Vijayaraghavan BK, Annane D, Cohen D, Arabi YM, Bolduc B, Marinoff N, Rochwerg B, Millen T, Meade MO, Hand L, R, Young PJ, D'Aragon F, Belley-Cote EP, Carbonneau E, Clarke F, Maslove DM, Hunt M, Chass\u00e9 M, Lebrasseur M, Lauzier F, Mehta S, Quiroz-Martinez Adhikari NKJ; LOVIT Investigators and the Canadian Critical Care Trials Group. Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit. N Engl J Med. 2022 15. PMID: 35704292. | | Vitamin D Governors of the University of Alberta (2020-07-27) | | PRO00100606 (Control #240943) Improving vitamin D status in the management of COVID-19 NCT04385940 | | Phase 3 Recruiting Start Date: 2021, March 19 Estimated study completion date: 2023, January | | Experimental: Vitamin D3 50 000 IU PO Active Comparator: Vitamin D3 1000 IU PO | | 17 years +, COVID-19 64 participants | | No results posted | | Vitamin D/Vitamin K-Vitamin D/Vitamin C/Zinc Ottawa Hospital Research Institute (2021-05-21) | | 20210072-01H (Control #251410) Dietary supplements to reduce symptoms severity and duration in people with SARS-CoV-2: A randomized, double-blind, placebo controlled clinical trial NCT04780061 | | Phase 3 Terminated Start date: 2021, July 12 Estimated completion date: 2022, Experimental: Cholecalciferol (Vitamin D3) 500mg 000units) one 1 then menaquione-7 (MK-7, vitamin K2) 0.114 ML twice daily, and cholecalciferol 1 000 units daily, and 2g ascorbic acid (vitamin C)/25mg zinc acetate combo three times a day for 21 days Placebo comparator: microcrystalline cellulose capsules and medium chain triglyceride oil | | 18+, SARS-CoV-2 positive, outpatient 200 participants | | Terminated (Public PCR testing stopped in Ontario) | | VIR-7831 Vir Biotechnology Inc. (2020-10-13) | | VIR-7831-5001 CTA (Control #244708) Filed under the Interim Order A randomized multi-center, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) in non-hospitalized patients NCT04545060 | | Phase 2/3 Completed Start date: 2020, August 27 Study completion date: 2021, September 2 | | Experimental: VIR-7831 IV infusion Placebo comparator: Normal saline (0.9% NaCl) IV infusion | | Adult, COVID19, high risk of COVID19 progression or >55 years 1057 participants | | No results posted | | VIR-7831 (GSK4182136) Vir Biotechnology Inc. (2021-04-09) | | 216912 (Control #250948) authorized under the clinical trials interim order A multicenter, randomized, double-blind, parallel group phase II study to evaluate the safety, tolerability and pharmacokinetics of a second generation VIR-7831 material in non-hospitalized participants with mild to moderate coronavirus disease 2019 (COVID-19) NCT04779879 | | Phase 2 Completed Study start date: 2021, February 18 Completion date: 2022, April VIR-7831 VIR-7831 (Gen1) IV | | 18+, SARS-CoV-2 positive, outpatient 352 participants | | No results posted | | Vortioxetine Brain and Cognition Discovery Foundation (2021-08-17) | #255061) Randomized, double-blinded, placebo-controlled study evaluating vortioxetine for cognitive deficits in persons with post-COVID-19 syndrome NCT05047952 | | Phase 2 Recruiting Study start date: September 16, 2021 Estimated completion date: 2023, January | | Experimental: Vortioxetine 10mg OD for 2 weeks, then OD for weeks 2-8 Placebo comparator: Placebo capsule OD for 8 weeks | | Adult (18-65), post-COVID-19 syndrome 200 participants | | No results posted | | Vaccine: Ad26.COV2.S (JNJ-78436735) Janssen Inc. (2020-12-14) | | VAC31518COV2001 (Control #246908) Authorized under clinical trials interim order A randomized, double-blind, placebo-controlled Phase 2a study to evaluate a range of dose levels and vaccination intervals of Ad26.COV2.S in healthy adults aged 18 to 55 years and older and to evaluate 2 dose levels of Ad26.COV2.S in healthy adolescents aged 12 to 17 years inclusive NCT04535453 | | Phase 2 Completed Start date: 2020, August 28 Completion date: 2022, March 9 | | Experimental: Groups 1-3 - Ad26.COV2.S, 2-dose regiment at different dose levels on day 1 and 57 Groups 4-5 - Ad26.COV2.S single dose Group 6 - placebo Group 7 - Ad26.COV2.S, 2-dose regiment at fixed dose level on day 1 and 29 Group 8 - placebo on day 1 and 29 Group 9 - Ad26.COV2.S, 2-dose regiment at fixed dose level on day 1 and 85 Group 10 - placebo on day 1 and 85 Group A & D- Ad26.COV2.S, 1-dose regiment at fixed dose plus a booster vaccination 12 months later Group B & E - Ad26.COV2.S, 2-dose regiment at fixed dose on Day 1 and 57 plus a booster vaccination 12 months later Group C & F- placebo, 2-dose regiment at fixed dose plus a booster vaccination 12 months later | | Ages 12-55 and 65+, healthy 635 participants | | Sadoff J, Le Gars M, Brandenburg B, C\u00e1rdenas V, F, Van Hoof J, Douoguih M, Schuitemaker H. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials. Vaccine. 2022 | | VAC31518COV2004 (Control #250107) Authorized under the clinical trials interim order An open-label, phase 2 study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.COV2.S in healthy pregnant participants NCT04765384 | | Phase 2 Active, not recruiting Start date: 2021, August 27 Estimated study completion date: 2024, May | | Experimental: Ad26.COV2.S IM injection on Day 1 and 57 | | 18-45 years, healthy, pregnant (between week 16-38) 51 participants | | No results posted | | Vaccine: AdCOVID Vaccine Altimmune, Inc. (2021-05-26) | | ALT-501-102 (Control #252058) Authorized under the Clinical Trials Interim Order A phase 1, open-label study to evaluate the effect of position and duration on the safety and immunogenicity of intranasal AdCOVID administration CT04679909 | | Phase 1 Active, not recruiting Start date: 2021, February 25 Estimated study completion date: 2022, February | | Experimental: Single low Experimental: Single intranasal Placebo comparator: dose placebo, intranasal Placebo comparator: Two dose placebo, intranasal | | 18-55 years, healthy 92 participants | | No results posted | | Vaccine: BNT162b2 mRNA | | 3750 (Control #255889) Authorized under the clinical trials interim order BOOST KIDNEY: A multi-centre 12 month parallel-group randomized control trial of BNT162b2 versus mRNA-1273 COVID-19 vaccine boosters in chronic kidney disease and dialysis patients with poor humoral response following COVID-19 vaccination NCT05022329 | | Phase 2/3 Active, not recruiting Study start date: September 30, 2021 Estimated study completion date: August 30, 2023 | | Experimental: BNT162b2 or mRNA-1273 SARS-CoV-2 vaccine, one dose IM | | Adult (18+), chronic kidney disease stage 3b-5, already received two-doses of a mRNA vaccine with the second dose being given 2-12 months previously 268 participants | | No results posted | | Vaccine: ChAd-CoV/Mac /Ad5-CoV/Mac McMaster University (2021-10-21) | | M010 (Control #257190) Phase 1, Open Label Study to Evaluate the Safety and Immunogenicity of ChAd68 and AdHu5 vector-based Trivalent COVID-19 Vaccine Delivered Via Inhaled Aerosol NCT05094609 | | Phase 1 Recruiting Start date: 2022, January 3 Estimated study completion date: 2023, December 31 | | Experimental: Ad5-triCoV/Mac 10e5 (low dose) single dose by inhalation dose) single dose by dose) single dose by ChAd-triCoV/Mac 10e6 (higher dose) single dose by inhalation | | 18-65 years, healthy, doubled vaccinated with mRNA vaccines 30 participants | | No results posted | | Vaccine: Coronavirus-like particle (CoVLP) COVID-19 Vaccine Medicago (Control #240922) A randomized, partially-blinded, dose-ranging phase 1 study to assess the safety, tolerability, and immunogenicity of a recombinant coronavirus-like particle COVID-19 vaccine in adults 18-55 years of age NCT04450004 | | Phase 1 Completed Start Date: 2020, July 10 Completion date: 2021, August 30 | | Experimental: Coronavirus-like particle COVID-19 Vaccine unadjuvanted 3.75ug IM on day 0 and Day 21 Experimental: Coronavirus-like particle COVID-19 Vaccine adjuvanted with CpG 1018 3.75ug IM on day 0 and Day 21 Experimental: Coronavirus-like particle COVID-19 Vaccine adjuvanted with AS03 3.75ug IM on day 0 and Day 21 Experimental: Coronavirus-like particle COVID-19 Vaccine unadjuvanted 7.5ug IM on day 0 and Day 21 Experimental: Coronavirus-like particle COVID-19 Vaccine adjuvanted with CpG 1018 7.5ug IM on day 0 and Day 21 Experimental: Coronavirus-like particle COVID-19 Vaccine adjuvanted with AS03 7.5ug IM on day 0 and Day 21 Experimental: Coronavirus-like particle COVID-19 Vaccine unadjuvanted 15ug IM on day 0 and Day 21 Experimental: Coronavirus-like particle COVID-19 Vaccine adjuvanted with CpG 1018 15ug IM on day 0 and Day 21 Experimental: Coronavirus-like particle COVID-19 Vaccine adjuvanted with AS03 15ug IM on day 0 and Day 21 | | 18-55 years, healthy 180 participants | | NWard BJ, Gobeil P, S\u00e9guin A, Atkins Couture M, D'Aoust MA, Dhaliwall J, Finkle C, Hager K, Mahmood A, Makarkov A, Cheng MP, Pillet S, Schimke P, St-Martin S, Tr\u00e9panier S, Landry N. Phase 1 randomized trial of a plant-derived virus-like particle vaccine Inc. (2020-11-09) | | CP-PRO-CoVLP-021 (CTA Control #245149) filed under the IO A randomized, observer-blind, placebo-controlled phase 2/3 study to assess the safety, efficacy, and immunogenicity of a recombinant coronavirus-like particle COVID-19 vaccine in adults 18 years of age NCT04636697 | | Phase 2/3 Completed Study start date: 2020, November 19 Estimated study completion date: 2022, April 30 | | Experimental: CoVLP adjuvanted vaccine with 0.5mL of AS03 doses IM 21days apart Placebo comparator: Placebo 0.5mL IM two doses 21 days apart | | 18+ years,healthy 24141 participants | | Completed - Showed benefit- Vaccine is 69.5% effective in preventing symptomatic COVID-19 infection and 78.8% effective against moderate-to-severe disease. Hager KJ, P\u00e9rez Marc G, Gobeil P, Diaz Heizer Makarkov AI, Vasconcellos E, Pillet S, Riera F, Saxena P, Geller Wolff P, Bhutada Wallace G, Aazami H, Jones CE, Polack L, Couture MMJ, Jiang-Wright Ceregido MA, Koutsoukos F, MA, Trepanier S, Kimura Y, Ward BJ; CoVLP Study Team. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. N (2022-09-28) | | COVAC-1 (Control # 267708) Authorized under the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations A Randomized, Observer-Blind, Dose Escalation, Placebo-Controlled, Phase 1 Clinical Trial To Study The Safety And Immunogenicity Of A Covac-1 Booster Dose In Generally Healthy Adults NCT05693272 | | Phase 1 Not yet recruiting Study start date: 2023, February 10 (estimated) Estimated study completion date: 2024, May 30 | | Experimental: COVAC-01 10\u00b5g COVAC-01 50\u00b5g IM one dose Placebo Comparator: saline IM one dose | | 18-65 years, healthy, two or more doses of COVID-19 vaccine(s) 48 participants | | No results posted | | Vaccine: COVAC-2 (nCoV19 S1) VIDO-InterVac, University of Saskatchewan (2020-12-22) | | COVAC-001 (Control #247198) Authorized under Clinical Trials Interim Order A randomized, observer-blind, dose-escalation Phase I/II clinical trial of COVAC vaccines in healthy adults NCT04702178 (Phase 1) NCT05209009 (Phase 2) | | Phase 1/2 Active, not recruiting (Phase 1); Recruiting (Phase 2) Study start date: 2021, February 10 (Phase 1); 2022, August 24 (Phase 2) Estimated study completion date: 2023, April (Phase 1); 2023, August (Phase 2) | | Experimental: COVAC-2 25microg IM injection two doses 28 days apart (Phase 1/2) Placebo comparator: Saline IM injection two doses 28 days apart (Phase 1/2) Experimental: COVAC-2 50microg IM injection two doses 28 days apart (Phase 1) Experimental: COVAC-2 100microg IM injection two doses 28 days apart (Phase 1) | | Healthy adults (18+) 72 participants (Phase 1); 300 participants (Phase 2) | | No results posted | | Vaccine: COVAC-2 (nCoV19 S1) University of Saskatchewan, VIDO (2021-12-23) | | COVAC-004 (Control #259104) Authorized under the Clinical Trials Interim Order A Phase 1/2 clinical trial to study the safety, tolerability, and immunogenicity of a COVAC-2 booster dose in generally healthy adults NCT05226702 | | Phase 1/2 Start date: 2022, July 22 Estimated completion date: 2023, December | Experimental: COVAC-2 10ug IM, one dose Experimental: COVAC-2 25ug IM, one dose Placebo comparator | | Generally healthy adults (18+), vaccinated or previous history of SARS-CoV-2 infection 380 participants | | No results posted | | Vaccine: Covigenix VAX-001 Entos Pharmaceuticals Inc. (2021-03-24) | | ENTVAX01-101 (Control #250321) Authorized under the Clinical Trials Interim Order Phase I/II study to evaluate safety, tolerability, immunogenicity of a prophylactic plasmid DNA vaccine against SARS CoV-2 [covigenix VAX-001] in healthy adults from 18 to < 85 years of age NCT04591184 | | Phase 1/2 Recruiting Study start date: 2021, April 7 Estimated study completion date: 2023, December | | Experimental: Covigenix VAX-001 two doses 14-42 days apart Placebo comparator: placebo injection | | 18-84 years, healthy 36 participants | | No results posted | | Vaccine: IMM-101 Canadian Cancer Trials Group, Cancer Research Institute, Queen's University (2020-06-24) | | IC.8 (Control #240586) Filed under the clinical trial interim order COV-IMMUNO- A randomized, Phase III trial of immunization with IMM-101 versus observation for the prevention of severe respiratory and COVID-19 related infections in cancer patients at increased risk of exposure NCT04442048 | | Phase 3 Active, not recruiting Start Date: 2020, June 25 Estimated study completion date: 2023, June 30 | | Experimental: IMM-101 Vaccine 1.0mg on day 0, then 0.5mg on Day 24, and 0.5mg on Day 45 (+/- 14 days) No intervention: No active treatment, observation only | | Adult, undergoing cancer-related treatment at a cancer clinic in hospital, have a risk factor for severe COVID-19 infection, have a life-expectancy of > 6 months, ECOG performance status <2, adequate organ function 195 participants | | No results posted | | Vaccine: mRNA-1273 SARS-CoV-2 vaccine (Moderna COVID-19 vaccine) ModernaTX, Inc (2021-07-08) | | mRNA-1273-P204 (Control #254169) Authorized under the clinical trials interim order A phase 2/3, two-part, open-label, dose-escalation, age de-escalation and randomized, the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to less than 12 years of age NCT04796896 | | Phase 2/3 Completed Start Date: Start date: March 15, 2021 Estimated study completion date: 2023, November 12 | | Experimental: mRNA-1273 vaccine 2 IM injections 28 days apart (Part 1- will assess 3 different doses, Part 2 will take the best dose forward) Placebo comparator: 0.9% sodium chloride injection (Part 2 only) | | Child (6 months to 11 years), healthy or stable chronic condition 13275 participants | | Two 25-g doses of the mRNA-1273 vaccine were found to be safe in children 6 months to 5 years of age and elicited immune responses that were noninferior to those in young adults. Anderson EJ, Creech CB, Berthaud V, Piramzadian A, Johnson KA, Zervos M, Garner F, Griffin C, Palanpurwala K, Turner M, Gerber J, Bennett RL, Ali K, Ampajwala M, Berman G, Nayak J, Chronis C, Rizzardi B, Muller WJ, Smith CA, Fuchs G, Hsia D, Tomassini JE, DeLucia D, Reuter C, Kuter B, Zhao X, Deng W, Zhou H, Ramirez Schrempp D, Hautzinger K, Girard B, Slobod K, McPhee Ghamloush S; KidCOVE Study Group. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. N Engl J Med. 2022 Oct 19. doi: 10.1056/NEJMoa2209367. Epub ahead print. PMID: 36260859. Two 50-g doses of the mRNA-1273 vaccine were found to be safe and effective in inducing immune responses and preventing Covid-19 in children 6 to 11 years of age; these responses were noninferior to those in young adults. Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I, Finkelstein D, Pickrell P, Kirstein J, Yut C, Blair R, Clifford RA, Dunn M, Campbell JD, Montefiori DC, Tomassini JE, Zhao X, Deng W, Zhou H, Ramirez Schrempp D, Hautzinger K, Girard B, Slobod K, Ghamloush S; KidCOVE Study Group. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. N Engl J Med. 2022 University Health Network (2021-04-26) | | UHN-TID-COVAX-2 (Control #251583) A randomised, single blind, controlled trial of third dose of Moderna vaccine versus placebo in solid organ transplant recipients NCT04885907 | | Phase 4 Completed Start date: 2021, May 25 Estimated completion date: 2021, August 30 | | Experimental: mRNA-1273 vaccine 0.5mL IM in deltoid muscle (3rd dose) Placebo Comparator: Normal saline 0.5mL IM in deltoid muscle | | 18+, solid organ transplant recipient who has previously received two doses of Moderna vaccine 120 participants | | In organ transplant recipients, a third dose of mRNA vaccine increases neutralizing antibody response against SARS-CoV-2 variants compared with placebo. Kumar D, Ferreira VH, Hall VG, Hu Q, Samson R, Ku T, Ierullo M, Majchrzak-Kita B, Tomlinson G, Gingras AC, Humar A. Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial. Ann Intern Med. | Moderna RCT LTCF (Control #255430) Authorized under the clinical trials interim order Third dose of moderna mRNA-1273 COVID-19 vaccine in residents of long-term care facilities NCT04978038 | | Phase 4 Not yet recruiting Study start date: 2022, August 1 (estimated) Estimated study completion date: 2022, December 31 | | Experimental: mRNA-1273 vaccine IM Active comparator: Pfizer Prevnar-13 pneumococcal vaccine 0.5mL IM | | 65+, long-term care resident and already received two doses of the mRNA-1273 vaccine 414 participants | | No results posted | | Vaccine: PTX-COVID19-B Providence Therapeutics Holdings Inc. (2020-12-22) | | PRO-CL-001 (Control #246974) Authorized under Clinical Trials Interim Order A Phase Ia/Ib, first-in-human, observer-blinded, randomized, placebo controlled, ascending dose study to evaluate the safety, tolerability, and immunogenicity of PTX-COVID19-B vaccine in healthy seronegative adults aged 18-64 and >65 NCT04765436 | | Phase 1 Active, not recruiting Study start date: 2021, January 14 Estimated study completion date: 2022, February 14 | | Experimental: 16microg or 40microg or 100 microg PTX-COVID19-B IM injection two doses 28 days apart Placebo comparator: 0.9% normal saline IM injection two doses 28 days apart | | Adults (18+), healthy 60 participants | | No results posted | | Vaccine: PTX-COVID19-B/Pfizer-BioNTech COVID-19 Vaccine Providence Therapeutics Holdings, Inc. (2021-07-20) | | PRO-CL-002 (Control # 253878) Authorized under the clinical trials interim order A Phase 2, randomized, observer-blind study to evaluate the safety, tolerability, and immunogenicity of PTX-COVID19-B compared to Pfizer-BioNTech COVID-19 Vaccine in healthy seronegative adults aged 18 to 64 years NCT05175742 | | Phase 2 Active, not recruiting Start date: 2021, August 17 Estimated completion date: 2023, March 31 | | Experimental: PTX-COVID19-B 40 ug IM, two doses 28 days apart Experimental: PTX-COVID19-B 60 ug IM, two doses 28 days apart Experimental: PTX-COVID19-B 80 ug IM, two doses 28 days apart Experimental: PTX-COVID19-B 40 ug IM, two doses 28 days apart and a placebo dose on Day 21 Active comparator: Pfizer-BioNTech COVID-19 vaccine, two doses 21 days apart and placebo dose on Day 28 | | 18-64 years, healthy 890 participants | | No results posted | | Vaccine: Recombinant Mycobacterium bovis BCG(delta)ureC::hly Princess Margaret Cancer Centre | (Control #238868) A randomized, double-blind, placebo-controlled phase 3 study: Efficacy and safety of recombinant BCG VPM1002 in reducing SARS-CoV-2 infection rate and COVID-19 severity NCT04439045 | | Phase 3 Completed Start Date: 2020, June 24 Estimated study completion date: 2021, comparator: Sodium chloride (0.9%) 0.1mL intradermal injection | | Adult, essential worker 122 participants | | No results yet posted | | Vaccine: Recombinant novel coronavirus vaccine (adenovirus Type 5) dose-escalation phase I/II clinical trial of Ad5-nCoV Vaccine in Healthy Adults from 18 to <85 years of age in Canada NCT04398147 | | Phase 1/2 Withdrawn Start Date: 2020, Aug 1 (estimated) Estimated study completion date: 2021, December 30 | | Experimental: Ad5-nCoV containing 5E10 vp IM (single dose) Placebo comparator: Placebo containing 0 vp IM Experimental: Ad5-nCoV containing 5E10 vp IM 2 doses 56 days apart Placebo comparator: Placebo containing 0 vp IM 2 doses 56 days apart Experimental: Ad5-nCoV containing 10E10 vp IM (single dose) Experimental: Ad5-nCoV containing 10E10 vp IM 2 doses 56 days apart | | Adult 18-84 years, healthy 696 participants | | Withdrawn | | Vaccine: SPIKEVAX (Moderna vaccine) (Elasomeran (mRNA)) Research Institute of McGill Health Centre (2021-11-08) | | MP-37-2021-7562 (Control # 258049) Authorized under the clinical trials interim order COVID-19 vaccine in immunosuppressed adults with autoimmune diseases NCT04806113 | | Phase 3 Active, not recruiting Start date: 2021, March 11 Estimated completion date: 2022, June 15 | | Experimental: Moderna mRNA vaccine two doses IM 28 days apart | | 18+, autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus) 220 participants | | No results posted | | COVB-2022-1 (Control # 261144) Authorized under the Clinical Trials Interim Order Covid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) NCT05236491 | | Phase 2/3 Recruiting Estimated start date: 2022, March 9 Estimated study completion date: 2023, January | | Experimental: Moderna dose) vaccine (Novaxovid) (one dose) | | 18+, diagnosed systemic autoimmune rheumatic disease, triple vaccinated 287 participants | | No results posted | | Vaccine: TAP-COVID-19 Kentucky Bioprocessing, Inc. (2021-05-03) | | KBP-201 (Control #251755) Authorized under the clinical trials interim order A phase I/II, first-in-human, observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of TAP-COVID-19 SARS-CoV-2 vaccine with CpG adjuvant in healthy seronegative adults aged 18-49 and 50-85 NCT04473690 | | Phase 1/2 Completed Start Date: 2020, October 14 Estimated completion date: 2022, December 31 | | Experimental: Low dose KBP-COVID-19 and adjuvant Experimental: High dose KBP-COVID-19 and adjuvant Placebo Comparator: Buffered saline solution | | Adult 18-85 years, healthy 101 participants | | No results posted | | Vaccine: Tozinemeran (Pfizer-BioNTech COVID-19 Vaccine) / ChAdOx1-S (2021-05-05) | | CT24 (Control #251972) Authorized under the clinical trials interim order ) Immunogenicity and adverse events following immunization with alternate schedules of authorized COVID-19 vaccines in Canada: MOSAIC study (Mix and match of second COVID-19 vaccine dose for safety and immunogenicity) NCT04894435 | | Phase 2 Recruiting Start date: 2021, May 20 Estimated study completion date: 2023, March | | Experimental: (Moderna, Moderna 28 days apart) mRNA-1273 SARS-CoV-2 vaccine 0.2mg/ml IM in deltoid muscle two doses 28 days apart Experimental: (Moderna, Moderna 112 days apart) mRNA-1273 SARS-CoV-2 vaccine 0.2mg/ml IM in deltoid muscle two doses 112 days apart Experimental: (Moderna, Pfizer/BioNTech 28 days apart) mRNA-1273 SARS-CoV-2 vaccine 0.2mg/ml IM in deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine 28 days apart Experimental: (Moderna, Pfizer/BioNTech days apart) mRNA-1273 SARS-CoV-2 vaccine 0.2mg/ml IM in deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine 112 days apart Experimental: (Pfizer/BioNTech, Pfizer/BioNTech 28 days apart) BNT162b2 vaccine 0.3mL IM in deltoid muscle two doses 28 days apart Experimental: (Pfizer/BioNTech, Pfizer/BioNTech 112 days apart) BNT162b2 vaccine 0.3mL IM in deltoid muscle two doses 112 days apart Experimental: (Pfizer/BioNTech, Moderna 28 days apart) BNT162b2 apart) ChAdOx1-S 0.5mL IM in muscle two doses 112 days apart Experimental: (AstraZeneca, Moderna 28 days apart) ChAdOx1-S 0.5mL IM in by BNT162b2 0.3mL apart Experimental: Pfizer/BioNTech 112 days 0.5mL IM in deltoid muscle followed by BNT162b2 0.3mL 112 days apart | | 18-99 years, Healthy or stable co-morbidities 1200 participants | | No results posted | | Vaccine: VBI-2902a VBI Vaccines Inc. (2020-12-18) | | VBI-2902a-CT01 (Control #246985) Authorized under the clinical trials interim order A Phase 1/2, randomized, observer-blind, dose-escalation, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of the COVID-19 (SARS-CoV-2) vaccine candidate (VBI-2902a) in healthy adults NCT04773665 | | Phase 1 Completed Study start date: 2021, March 15 Estimated study completion date: 2022, November 14 | | Experimental: VBI-2902a (enveloped virus-like particle with aluminum phosphate adjuvant) with 5microg of S protein IM injection one dose + placebo 28 days later Experimental: VBI-2902a (enveloped virus-like particle with aluminum phosphate adjuvant) with 5microg of S protein IM injection two doses 28 days apart Placebo comparator: 0.9% sodium chloride (normal saline) IM injection two doses 28 days apart Experimental: VBI-2902a (enveloped virus-like particle with aluminum phosphate adjuvant) with 10microg of S protein IM injection one dose + placebo 28 days later Experimental: VBI-2902a (enveloped virus-like particle with aluminum phosphate adjuvant) with 10microg of S protein IM injection two doses 28 days apart | | Adult (18+), healthy 114 participants | | No results yet posted | | Vaccine: VBI-2902a Variation Biotechnologies Inc. (2022-09-15) | | VBI-2901A (Control # 267517) Authorized under the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations A Phase 1, Randomized Study To Evaluate The Safety And Immunogenicity Of VBI- 2901a, A Trivalent Coronavirus Vaccine Candidate In Healthy Adults Previously Vaccinated With Licensed Covid-19 Vaccines NCT05548439 | | Phase 1 Active, not recruiting Start date: October 5, 2022 Estimated Completion date: 2024, February | | Experimental arm: VBI-2901a 5 \u00b5g IM at Day 1 and Day 56 Experimental arm: VBI-2901a 10 \u00b5g IM at Day 1 and Day 56 Experimental arm: VBI-2901a 10 \u00b5g IM at Day 1 | | 18-64 years, healthy, previously received two or more doses of COVID-19 vaccine(s) 103 participants | | No results yet posted | | Vaccine:VBI-2901E Variation Biotechnologies Inc. (2022-10-25) | | VBI-2901E (Control # 268572) Authorized under the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations A Phase 1, Open-Label, Adjuvant Dose-Escalation, Randomized Study To Evaluate The Safety And Immunogenicity Of Vbi-2901e, A Trivalent Coronavirus Vaccine Candidate Adjuvanted With Aluminum Phosphate And E6020 In Healthy Adults Previously Vaccinated With Licensed Covid-19 Vaccines NCT05614245 | | Phase 1 Not yet recruiting Start date: 2023, March (estimated) Estimated Completion date: 2024, June | | Experimental: VBI-2901e 5 E6020 VBI-2901e 5 \u00b5g and 1 \u00b5g E6020 IM at Day 1 and Day 28 Experimental: VBI-2901e 5 \u00b5g and 3 \u00b5g E6020 VBI-2901e 5 \u00b5g and 3 \u00b5g E6020 IM at Day 1 and Day 28 Experimental: VBI-2901e 5 \u00b5g and 1 \u00b5g E6020 VBI-2901e 5 \u00b5g and 10 \u00b5g E6020 IM at Day 1 and Day 28 | | 18-40 years, healthy, received two or more doses of COVID-19 vaccine(s) 60 participants | | No results yet posted "}